Dermata Therapeutics Net Worth
Dermata Therapeutics Net Worth Breakdown | DRMAW |
Dermata Therapeutics Net Worth Analysis
Dermata Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Dermata Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Dermata Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Dermata Therapeutics' net worth analysis. One common approach is to calculate Dermata Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Dermata Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Dermata Therapeutics' net worth. This approach calculates the present value of Dermata Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Dermata Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Dermata Therapeutics' net worth. This involves comparing Dermata Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Dermata Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Dermata Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Dermata Therapeutics' net worth research are outlined below:
| Dermata Therapeutics is way too risky over 90 days horizon | |
| Dermata Therapeutics has some characteristics of a very speculative penny stock | |
| Dermata Therapeutics appears to be risky and price may revert if volatility continues | |
| Dermata Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (7.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Dermata Therapeutics generates negative cash flow from operations | |
| Dermata Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Dermata Secures Key Patent for Revolutionary Acne Treatment DMT310 Ahead of Phase 3 Results - StockTitan |
Project Dermata Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.98) | (1.03) | |
| Return On Capital Employed | (1.27) | (1.33) | |
| Return On Assets | (0.98) | (1.03) | |
| Return On Equity | (1.23) | (1.29) |
When accessing Dermata Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Dermata Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Dermata Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Dermata Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Dermata Therapeutics Warrant. Check Dermata Therapeutics' Beneish M Score to see the likelihood of Dermata Therapeutics' management manipulating its earnings.
Evaluate Dermata Therapeutics' management efficiency
The company has return on total asset (ROA) of (0.9068) % which means that it has lost $0.9068 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.7301) %, meaning that it generated substantial loss on money invested by shareholders. Dermata Therapeutics' management efficiency ratios could be used to measure how well Dermata Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.03 in 2024. Return On Capital Employed is likely to drop to -1.33 in 2024. Debt To Assets is likely to climb to 5.53 in 2024, whereas Total Assets are likely to drop slightly above 6.4 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 32.76 | 34.40 | |
| Tangible Book Value Per Share | 32.76 | 34.40 | |
| Enterprise Value Over EBITDA | (20.62) | (21.65) | |
| Price Book Value Ratio | 0.28 | 0.29 | |
| Enterprise Value Multiple | (20.62) | (21.65) | |
| Price Fair Value | 0.28 | 0.29 | |
| Enterprise Value | 70.8 M | 67.2 M |
Evaluating the management effectiveness of Dermata Therapeutics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Dermata Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Return On Equity (1.73) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dermata Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dermata Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Dermata Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
David Hale over six months ago Acquisition by David Hale of 10000 shares of Dermata Therapeutics at 0.6099 subject to Rule 16b-3 | ||
Fisher Mary over six months ago Acquisition by Fisher Mary of 5000 shares of Dermata Therapeutics at 1.88 subject to Rule 16b-3 | ||
Sandler Andrew Seth over six months ago Acquisition by Sandler Andrew Seth of 10000 shares of Dermata Therapeutics at 0.6099 subject to Rule 16b-3 | ||
Bedoya-toro Munera Maria E over six months ago Acquisition by Bedoya-toro Munera Maria E of 15000 shares of Dermata Therapeutics at 1.88 subject to Rule 16b-3 |
Dermata Therapeutics Earnings per Share Projection vs Actual
Dermata Therapeutics Corporate Management
| Mr MPH | VP Devel | Profile | |
| Maria MBA | Senior Assurance | Profile | |
| Gerald Proehl | Chairman, CoFounder | Profile | |
| Kyri Hoose | VP CFO | Profile | |
| Sean Proehl | Senior Development | Profile | |
| Dr MPH | Senior Officer | Profile |
Additional Tools for Dermata Stock Analysis
When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.